EGFR and nasopharyngeal carcinoma: Our recent study demonstrated that R/M NPC patients who had progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR agents with or without chemotherapy27.